| Dr Megan A Mezera, MD | |
|
Two Cooper Plaza 400 Haddon Ave, Camden, NJ 08103 | |
| (855) 632-2667 | |
| (856) 735-6467 |
| Full Name | Dr Megan A Mezera |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 14 Years |
| Location | Two Cooper Plaza 400 Haddon Ave, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477865426 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 25MA10277400 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cooper University Hospital | Camden, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiation Oncology Pc | 6305747601 | 8 |
News Archive
Researchers from UPM have taken the first steps towards the development of a sensor for the detection of bacterial meningitis in real time by combining gravimetric sensors with synthetic antibodies giving, as a result, a sensitive, rapid and affordable method.
Women who drink alcohol at moderate or heavy levels in the early stages of their pregnancy might damage the growth and function of their placenta - the organ responsible for supplying everything that a developing infant needs until birth - research at The University of Manchester shows.
Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.
The Lupus Foundation of America (LFA) applauds Congress for including vital lupus funding in the Fiscal Year 2012 Omnibus Appropriations Bill, which passed today, Saturday, December 17.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
› Verified 4 days ago
| Entity Name | Radiation Oncology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154369163 PECOS PAC ID: 6305747601 Enrollment ID: O20040120000092 |
News Archive
Researchers from UPM have taken the first steps towards the development of a sensor for the detection of bacterial meningitis in real time by combining gravimetric sensors with synthetic antibodies giving, as a result, a sensitive, rapid and affordable method.
Women who drink alcohol at moderate or heavy levels in the early stages of their pregnancy might damage the growth and function of their placenta - the organ responsible for supplying everything that a developing infant needs until birth - research at The University of Manchester shows.
Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.
The Lupus Foundation of America (LFA) applauds Congress for including vital lupus funding in the Fiscal Year 2012 Omnibus Appropriations Bill, which passed today, Saturday, December 17.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Megan A Mezera, MD 1 Federal St Ste Sw200, Camden, NJ 08103-1155 Ph: (856) 356-4924 | Dr Megan A Mezera, MD Two Cooper Plaza 400 Haddon Ave, Camden, NJ 08103 Ph: (855) 632-2667 |
News Archive
Researchers from UPM have taken the first steps towards the development of a sensor for the detection of bacterial meningitis in real time by combining gravimetric sensors with synthetic antibodies giving, as a result, a sensitive, rapid and affordable method.
Women who drink alcohol at moderate or heavy levels in the early stages of their pregnancy might damage the growth and function of their placenta - the organ responsible for supplying everything that a developing infant needs until birth - research at The University of Manchester shows.
Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.
The Lupus Foundation of America (LFA) applauds Congress for including vital lupus funding in the Fiscal Year 2012 Omnibus Appropriations Bill, which passed today, Saturday, December 17.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
› Verified 4 days ago
Thomas Jonathan Presenza, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Radiology Dept, Camden, NJ 08103 Phone: 856-342-2380 Fax: 856-365-0472 | |
Allison Solish Gittens, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, B23, Camden, NJ 08103 Phone: 856-342-2588 | |
Dr. Maria Christina Sciotto, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Robyn G Roth, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2380 | |
Dr. Todd Loring Siegal, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Cooper University Radiology, Pc, Camden, NJ 08103 Phone: 856-342-2383 Fax: 856-365-0472 | |
Dr. Stuti Ahlawat, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Two Cooper Plaza 400 Haddon Ave, Camden, NJ 08103 Phone: 855-632-2667 Fax: 856-735-6467 | |
Vivek Sehgal, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 888-499-8779 |